KLI
ATRS

Kelman-Lazarov Inc’s Antares Pharma, Inc. ATRS Stock Holding History

Kelman-Lazarov Inc’s Portfolio ATRS Stock Details ATRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-15,000
Closed -$62K – 90
2021
Q1 		$62K Hold
15,000
– – 0.02% 84
2020
Q4 		$60K Hold
15,000
– – 0.02% 85
2020
Q3 		$41K Hold
15,000
– – 0.02% 72
2020
Q2 		$41K Buy
+15,000
New +$41.9K 0.02% 76

Other funds holding ATRS

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SIG
Sargent Investment Group Bethesda, Maryland $759M AUM 28.58% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
FWSM
First Wilshire Securities Management Pasadena, California $444M AUM 42.88% 1-Year Est. Return
Amundi
Amundi Paris, France $367B AUM 31.23% 1-Year Est. Return

Kelman-Lazarov Inc's ATRS Position: Q2 2021 in Review

Kelman-Lazarov Inc sold out of Antares Pharma, Inc. (ATRS) in Q2 2021, closing a stake of 15,000 shares — an estimated $62K sold.

Kelman-Lazarov Inc first reported a position in ATRS in Q2 2020 and held it in 4 quarters. The position peaked at $62K in Q1 2021. 175 funds tracked by Wall St. Rank hold ATRS as of Q2 2021.

  • Kelman-Lazarov Inc reported no remaining Antares Pharma, Inc. position as of Q2 2021 after selling out during the quarter.
  • Kelman-Lazarov Inc sold 15,000 Antares Pharma, Inc. shares in Q2 2021, an estimated $62K.
  • Kelman-Lazarov Inc first reported a position in Antares Pharma, Inc. in Q2 2020 and held it in 4 quarters.
  • Kelman-Lazarov Inc's Antares Pharma, Inc. position peaked at $62K in Q1 2021.
  • 175 funds tracked by Wall St. Rank held Antares Pharma, Inc. as of Q2 2021.

Based on Kelman-Lazarov Inc's 13F filing for Q2 2021, filed 10 Aug 2021.